PRESERVATION OF LYMPHOKINE-ACTIVATED KILLER ACTIVITY FOLLOWING T CELL DEPLETION OF HUMAN BONE MARROW
- 1 October 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 50 (4) , 625-631
- https://doi.org/10.1097/00007890-199010000-00020
Abstract
T cell depletion has decreased the incidence and severity of graft-versus-host disease following transplantation of allogeneic bone marrow. In the treatment of leukemia, decreased GVHD has often been associated with diminished antileukemia or graft-versus-leukemia (GVL) reactivity resulting in higher relapse rates. However, we have not seen a loss of the GVL effect following transplantation of marrow grafts depleted of CD3+ T cells. This suggest that non-T-cell effectors may play a role in preventing leukemic relapse. To study whether natural killer and lymphokine-activated killer (LAK) activity in BM was compromised by T cell depletion, the effect of T-cell-specific monoclonal antibodies against CD3 and CD6 determinants alone, or in combination, on the generation and expansion of NK/LAK cells was examined in vitro and compared to the effect of T depletion on mitogen-driven T cell proliferation. Limiting dilution analysis revealed that T depletion with CD3 and/or CD6 specific antibodies significantly reduced the number of proliferating T lymphocytes but did not significantly affect the frequency of cells able to expand and mediate LAK activity. Bone marrow, depleted of CD3+ or CD6+ T cells, generated levels of LAK activity equivalent to non-T-cell-depleted bone marrow following long-term culture in recombinant interleukin 2. CD3- NKH-1+ cells were the predominant population in rIL-2 expanded marrow cultures prior to transplant and in the peripheral blood of patients who had received a CD3-depleted marrow graft 21-65 days earlier. These studies show that is possible to selectively reduce GVH-reactive T cells in allogeneic bone marrow while retaining non-T-effector cells with potential to mediate an antileukemia effect in vivo.This publication has 24 references indexed in Scilit:
- Bone Marrow Transplantation for Chronic Myelogenous Leukemia in Chronic PhaseAnnals of Internal Medicine, 1988
- Treatment of Donor Bone Marrow with Monoclonal Anti-T-Cell Antibody and Complement for the Prevention of Graft-Versus-Host DiseaseAnnals of Internal Medicine, 1986
- Natural killer cell activity following T-cell depleted allogeneic bone marrow transplantationBritish Journal of Haematology, 1986
- REACTIVITY OF IN-VITRO-EXPANDED ALLOIMMUNE CYTOTOXIC T LYMPHOCYTES and Qa-1-SPECIFIC CYTOTOXIC T LYMPHOCYTES AGAINST AKR LEUKEMIA IN VIVO1Transplantation, 1985
- ELIMINATION OF GRAFT-VERSUS-HOST DISEASE BY IN-VITRO DEPLETION OF ALLOREACTIVE LYMPHOCYTES WITH A MONOCLONAL RAT ANTI-HUMAN LYMPHOCYTE ANTIBODY (CAMPATH-1)The Lancet, 1984
- DEPLETION OF T LYMPHOCYTES IN DONOR MARROW PREVENTS SIGNIFICANT GRAFT-VERSUS-HOST DISEASE IN MATCHED ALLOGENEIC LEUKAEMIC MARROW TRANSPLANT RECIPIENTSThe Lancet, 1984
- EX-VIVO TREATMENT OF DONOR BONE MARROW WITH ANTI-T-CELL IMMUNOTOXINS FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASEThe Lancet, 1984
- POSSIBILITY OF GRAFT-VS-LEUKEMIA DETERMINANTS INDEPENDENT OF THE MAJOR HISTOCOMPATIBILITY COMPLEX IN ALLOGENEIC MARROW TRANSPLANTATIONTransplantation, 1983
- Limiting dilution assays for the determination of immunocompetent cell frequencies. I. Data analysis.The Journal of Immunology, 1981
- Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow GraftsNew England Journal of Medicine, 1979